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Reportedly, fibromyalgia (FM) is frequently associated with reduced IGF-1 levels and GH hyporesponsiveness to different
GH stimulation tests. Since there is a high prevalence of obesity in FM, and obesity itself is characterized by
hyposomatotropism, the aim of this study was to assess IGF-1 levels and GH responsiveness in sixteen severely obese
women suffering from FM, who, subdivided into two subgroups on the basis of their age-dependent IGF-1 values (> or
<−2 SDS), underwent the combined GHRH plus arginine test. Four out of 16 obese women with FM (25%) had low
IGF-1 SDS values, 2 cases of this subgroup (12.5%) failing also to normally respond to the test. Among patients with
normal GH responses, 4 showed a delayed GH peak. The subgroup with low IGF-1 SDS values had higher BMI than
that with normal IGF-1 SDS. GH peak and area under the curve were not correlated with CRP, ESR, or tender point
score, while significant correlations were found with fat-free mass and fat mass. In conclusion, this study shows the
existence of a high prevalence of GH-IGF-1 dysfunction in patients with both FM and obesity, presumably as a
consequence of the obese rather than fibromyalgic condition.
1. Introduction
Fibromyalgia (FM) is currently viewed as a common clinical
syndrome characterized by widespread musculoskeletal
pain and decreased pain threshold to pressure and other
stimuli. However, the large majority of patients suffering
from FM also experience other complaints, such as fatigue
after mild physical efforts, morning stiffness, sleep disorders
(nonrestorative sleep and insomnia), cognitive disturbances
(especially, loss of memory), irritable bowel syndrome,
headache, paraesthesia, and increased lifetime psychiatric
comorbidity, mainly depression and anxiety disorders [1].
Depending on the diagnostic criteria used, the prevalence
of FM is from 2% to 10% of the general population and
about 20% among the outpatients attending rheumatology
clinics [2].
Although the aetiology of FM remains unclear, low levels
of insulin-like growth factor 1 (IGF-1), the main biological
effector of growth hormone (GH) peripheral actions, are
found in a subgroup of subjects suffering from FM [3].
Furthermore, GH stimulation tests frequently reveal a
suboptimal GH responsiveness, which is however not always
related with low IGF-1 levels [4].
The diagnosis of GH deficiency (GHD) is not rare in
fibromyalgic patients, who often show signs and symptoms
resembling the clinical picture of adult GHD [4]. As
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documented in some randomized placebo-controlled stud-
ies, only few months of daily recombinant human GH
(rhGH) are able to reduce symptoms related to FM,
including pain, to normalize IGF-1 levels and to improve
quality of life [5].
Obesity is a complex disease, defined as a condition of
excessive accumulation of body fat. Obesity is characterized
by hyposomatotropism, as documented by reduced GH
responses to physiological and pharmacological stimuli,
being serum IGF-1 levels generally normal-to-high [6].
There is a strong evidence that obese individuals
complain more of musculoskeletal pain and physical dys-
function than people of normal weight [7]. Obesity seems
to be associated with some rheumatologic conditions, the
most significant association being with FM. In this context,
Ursini et al. [8] demonstrated the existence of an epidemio-
logical correlation between these two pathological condi-
tions, with a prevalence of obesity in fibromyalgic patients
of about 40%.
This link is clinically relevant because the fibromyalgic
obese group exhibits lower performance capacity and higher
disability level as compared with the nonfibromyalgic obese
group [9]. Obesity can be considered an aggravating comor-
bid condition, affecting negatively FM severity, global quality
of life, fatigue, and physical dysfunction.
Weight loss induced by bariatric surgery was reported to
reduce pain and tender point scores in patients with both
obesity and FM, with a relevant improvement of quality of
life [10]. It is noteworthy that any intervention aimed at
reducing body weight in obese or overweight subjects is
followed by a normalization of somatotropic function [6],
which in turn might be involved in these positive effects.
Current medical therapy for obesity, however, has limited
effectiveness on weight loss maintenance. Consequently,
some authors have proposed to use rhGH also in obesity
for its lipolytic and weight-reducing effects [11]. Anyway,
further studies are needed before adopting this hormone
therapy in clinical practice for obese subjects.
Although the state of hyposomatotropism may be
present in either obesity or FM, to our best knowledge, no
study has evaluated the somatotropic function in severely
obese patients suffering from FM so far. Therefore, the
present study was carried out with the aim of determining
the proportion of individuals with low serum IGF-1 levels
and/or failing to respond to the combined GH-releasing
hormone (GHRH) plus arginine test in a cohort of FM
subjects with severe obesity.
2. Materials and Methods
2.1. Patients. Sixteen adult female patients, aged 18–51
years (mean± SD: 36.5± 10.4 years), severely obese (body
mass index, BMI range: 37.4–60.6 kg/m2; mean BMI:
43.6± 6.2 kg/m2), recruited at the Division of Metabolic
Diseases, Istituto Auxologico Italiano, Verbania, Italy, were
included in the study. All patients, who complained of
FM-related symptoms since at least seven months, were
diagnosed to suffer from FM by using the 2010 ACR diagnos-
tic criteria for FM [12]. Other rheumatologic diseases were
excluded by clinical examination and X-ray imaging. A part
from FM and obesity, no evident signs and symptoms that
can be related with clinical endocrine conditions were
present. PCOS (polycystic ovary syndrome) and hypothy-
roidism were excluded by a pelvic echography and hormonal
evaluations, as appropriate.
All patients had regular menses, and their enrolment
into the study was carried out at the start of their follicular
phase. No woman was taking drugs affecting GH secretion,
including antidepressants, antiepileptic drugs, tramadol,
and oral estrogens.
Physical examination included determination of height
and weight in fasting conditions and after voiding. Stand-
ing height was determined by a Harpenden Stadiometer
(Holtain Ltd., Dyfed, UK). Body weight was measured to
the nearest 0.1 kg, by using standard equipment. BMI
was defined as weight in kilogrammes divided by the square
of height in metres. Waist circumference was measured in
standing position halfway between the inferior margin of
the ribs and the superior border of the crista. Hip circum-
ference was measured as the greatest circumference
around the nates.
Fat-free mass and fat mass were evaluated by bioelec-
trical impedance analysis (Human-IM Scan, DS-Medigroup,
Milan, Italy) and expressed as kg and percentage.
The entire study protocol was approved by the ad hoc
Ethical Committee of Istituto Auxologico Italiano. Written
informed consent was obtained from all participants.
2.2. Endocrine Protocol. All subjects underwent a standard
GHRH plus arginine test, which was performed within one
week from the diagnosis of FM. Tests started at 08:30 AM
after overnight fasting, with the patients recumbent. Fifteen
minutes after an indwelling catheter had been placed in
an antecubital vein, each subject received GHRH (1-29)
injection (GHRH, Ferring GmbH, Kiel, Germany; 1μg/kg
as i.v. bolus at 0min). From 0 to 30min after GHRH
administration, 0.5 g/kg (maximum dose 30 g) of arginine
hydrochloride (SALF, Bergamo, Italy) was infused. Blood
samples for GH determination were drawn at −15, 0, 30,
45, 60, 90, and 120min. GHD was classified according to
a GH peak value to GHRH plus arginine test lower than
4.2 ng/ml [13]. This stringent criterion was used because
it has been shown to have the highest values of sensitivity
and specificity when diagnosing GHD in adult obesity
[13] and to minimize the misclassification of obese FM
patients as GH-deficient subjects when this was not the
case [14].
Baseline blood samples were drawn for determination
of C-reactive protein (CRP), erythrocyte sedimentation rate
(ESR), and IGF-1 (see below).
IGF-1 levels were expressed as standard deviation score
(SDS) from an age-matched reference value, considering
those normal subjects with IGF-1 SDS above −2 and those
abnormal subjects with IGF-1 SDS below −2. Depending on
IGF-1 SDS values, the study population was thus divided
into two subgroups (subgroup>−2 SDS: 12 subjects; sub-
group<−2 SDS: 4 subjects).
2 International Journal of Endocrinology
2.3. Hormonal and Biochemical Measurements. Serum GH
concentrations were determined by a commercially avail-
able immunometric chemiluminescence kit (Immulite 2000,
DPC, Los Angeles, CA, USA). The international standard
for recombinant human GH NIBSC Code 98/574 was used
as standard material. Intra- and interassay coefficients of
variation (CV) for this assay were 2.5% and 6%, respec-
tively. The sensitivity of the method was 0.01 ng/ml.
Serum IGF-1 concentrations were determined by the
commercially available immunometric chemiluminescence
assay Immulite 2000 (DPC; Los Angeles, USA). The interna-
tional standard for recombinant human IGF-1 NIBSC Code
02/254 was used as a standard material. Intra- and interassay
CVs were 2.9% and 7.4%, respectively. The sensitivity of the
assay was 20ng/ml.
A high-sensitivity immunochemiluminescent method
was used to measure serum levels of RCP (Immulite 2500,
DPC; Los Angeles, USA), being the analytical sensitivity
0.01mg/dl. The intra- and interassay CVs were <8.7% for
both parameters.
ESR was measured by a microspectrophotometer with
the stopped flow technique (Alifax). The intra- and inter-
assay CVs were 5%.
For each parameter, all of a single subject’s samples
were run in the same assay and the order of tubes in
the assay was randomized. All CVs above reported were
periodically confirmed in our laboratory by using specific
controls of quality.
2.4. Statistical Analysis. All data were presented as means
(±standard deviation, SD). Areas under curve (AUCs) of
GH were calculated by the trapezoidal method.
Gaussian distribution was verified for each parameter
before applying any parametric statistical test. GH concen-
trations were compared within each group (versus basal
value, that is, at T0) and among the two groups (i.e., subjects
with normal or low IGF-1 SDS values) using a two-way
ANOVA with repeated measures followed by the post hoc
Bonferroni’s test. The Student t-test for unpaired data was
used to compare the demographic, clinical, and hormonal
characteristics between the two groups with normal or low
IGF-1 SDS values. Correlations between peak and AUC
values of GH with the other parameters were calculated by
the least squares regression approach. Statistical significance
was set at p < 0 05.
3. Results
Demographic, clinical, and hormonal characteristics of the
study population are reported in Table 1 (all data and
subjects with normal or low IGF-1 SDS values, resp.).
Among the entire group, 3 patients had a tender point
score of 13/18, 7 of 14/18, 2 of 15/18, 2 of 16/18, and
2 of 18/18.
Four out of 16 obese women with FM (25%) had low
IGF-1 SDS values (PT#13, PT#14, PT#15, and PT#16). This
subgroup had significantly higher BMI values than normal
IGF-1 SDS values. By contrast, there were no statistically
significant differences in age, fat mass, fat-free mass, hip,
and waist between the two subgroups.
GHRH plus arginine administration evoked a significant
increase in GH levels (at T30, T45, T60, and T90 versus
T0, p < 0 05) in the entire population and in the two sub-
groups with normal or low IGF-1 SDS values (Figure 1).
GH response in subjects with low IGF-1 SDS values was
significantly reduced when compared to that in the sub-
group with normal IGF-1 SDS values (at T60 and T90,
p < 0 05) (Figure 1).
Considering all patients, the rate of failure in GH
response to the combined GHRH plus arginine test was
12.5% (2 out of 16 patients, PT#13 and PT#14, both
belonging to the subgroup with low IGF-1 SDS values)
(Figure 2). Among patients with normal GH responses, 4
showed a delayed GH peak (3 at T90 and 1 at T120)
(Figure 2). A delayed GH peak was also found in 1 subject
with GHD (at T90) (Figure 2).
The two GH deficient patients were further investigated
to exclude the existence of other pituitary hormonal deficien-
cies. No other pituitary deficiencies were found.
The most relevant significant correlations were the ones
between peak GH or GH AUC and height (r = 0 656 and
r = 0 657, p < 0 01), fat-free mass in kg (r = 0 564 and
r = 0 555, p < 0 01), fat-free mass in percent (r = 0 492 and
r = 0 554, p < 0 05), and fat mass in percent (r = −0 492
and r = −0 554, p < 0 05), respectively. On the contrary, no
correlations between GH peak or GH AUC and tender point
score, ESR, and CRP were found. Finally, peak GH was
positively correlated with IGF-1 levels (r = 0 133, p < 0 05).
Table 1: Demographic, clinical, and hormonal characteristics of the
obese women with fibromyalgia syndrome included in the study.
Parameter All data
IGF-1
SDS>−2
IGF-1
SDS<−2
Number 16 12 4
Age (yrs) 36.5± 10.4 36.5± 10.5 36.8± 11.8
BMI (kg/m2) 43.6± 6.2 41.8± 4.2 48.9± 8.8∗
Waist (cm) 126.4± 11.1 123.9± 9.9 134.0± 12.6
Hip (cm) 133.8± 13.1 131.1± 6.4 141.8± 24.5
Fat mass (kg) 61.6± 12.9 58.6± 8.2 70.6± 19.8
Fat mass (%) 54.1± 4.7 53.0± 4.4 57.2± 4.6
Fat-free mass (kg) 51.6± 4.2 51.5± 3.6 51.7± 6.3
Fat-free nass (%) 46.0± 4.7 47.0± 4.4 42.8± 4.6
Tender-point score 14.7± 1.6 14.5± 1.5 15.3± 1.9
ESR (mm/h) 33.9± 18.7 34.8± 19.5 31.5± 18.7
CRP (mg/dl) 1.2± 1.2 0.9± 0.8 2.1± 2.1
IGF-1 (ng/ml) 138.1± 71.0 160.7± 66.2 70.5± 31.2∗
IGF-1 SDS −1.1± 0.9 −0.7± 0.7 −2.3± 0.1∗
Peak GH (ng/ml) 10.4± 5.2 11.7± 5.0 6.7± 4.5
GH AUC
(ng×min/ml) 716.7± 392.4 812.8± 391.4 428.3± 245.6
∗
∗p < 0 05 versus group with IGF-1 SDS > −2. BMI: body mass index; ESR:
erythrocyte sedimentation rate; CRP: C-reactive protein; IGF-1: insulin-
like growth factor 1; GH: growth hormone; AUC: area under the curve.
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4. Discussion
A significant number of fibromyalgic patients are reported
to have a somatotropic dysfunction [4]. Particularly,
Cuatrecasas et al. [3] found reduced IGF-1 levels (150 ng/ml
or less) in approximately 34% of overweight (BMI= 27.2±
4.1 kg/m2) patients with severe FM. The same authors
reported a reduced GH peak (< 5ng/ml) to insulin-induced
hypoglycaemia test in 17% of subjects, 6% of patients
having a GH peak equal to or less than 3ng/ml [3]. In
another clinical study performed in fibromyalgic patients
with a mean BMI of about 30 kg/m2, 17% of patients
tested with GHRH plus arginine failed to respond above
a cutoff of 4.2 ng/ml [14].
Differently from the above reported cohorts, the present
study was carried out in a group of patients with both severe
obesity (mean BMI: 43.6± 6.2 kg/m2) and FM. Twenty-five
percent of our subjects had markedly low IGF-1 levels (less
than −2 SDS, according to age), while 12.5% of them were
GH deficient, accordingly with a cutoff value of 4.2 ng/ml,
which is suggested to be used when testing obese subjects
[13]. Moreover, a delayed GH peak was found in 5 patients
(31%), 4 with normal GH-stimulated levels, and 1 showing
an impaired GH response to the stimulus. This delayed GH
peak is an important finding because it can be considered
suggestive of a dysfunction in the hypothalamic regulation
network of GH secretion, involving the interplay of both
GHRH and somatostatin tone [15].
Our results (i.e., the prevalence of low IGF-1 levels and
the rate of GHD in patients with both FM and obesity)
are slightly lower than or similar to those obtained in fibro-
myalgic patients with lower BMI (i.e., lean, overweight, and
moderately obese subjects), thus suggesting that the there is
no “additive” effect between the hyposomatotropism present
in obesity and the somatotropic dysfunction in FM. These
data are also in line with those reported by Maccario et al.
[16], who showed a reduction of GH response to GHRH plus
arginine in 33.9% of (nonfibromyalgic) obese subjects (taking
into account the 1st centile limit of normal response) and low
IGF-1 levels in 22%. In the same work, considering 3.0 ng/ml
as arbitrary cutoff, GH response was reduced in 5.7% of obese
patients, one of them having low IGF-1 levels (1.9%).
Based on these considerations, we may argue that the
mechanisms underlying the hyposomatotropism in obesity
and the somatotropic dysfunction in FM are likely to be
common, presumably an imbalance in neurotransmitters
and/or neuropeptides at the sovra- or intrahypothalamic
level, an alteration which has been invoked to explain some
symptoms present in FM, such as chronic pain, sleep
disturbances, psychiatric disorders (mainly anxiety and
depression), and other neuroendocrine dysfunctions [17].
In this light, it is interesting to recall that pyridostigmine,
an anticholinesterase inhibitor, capable of reducing hypo-
thalamic somatostatin tone, was reported to improve
exercise-induced GH release in patients suffering from
FM, thus suggesting the existence of a somatostatin hyper-
tone, a condition that has been supposed to occur also in
obesity [18].
This interpretation is, obviously, valid for the cases of
GHD deriving from neurosecretory dysfunction and not
organic hypothalamus-pituitary diseases, which can be
identified in fibromyalgic patients with GHD [14].
A high prevalence of obesity has been found in FM, and
obesity is considered to be a relevant risk factor for FM [8].
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Figure 1: Serum concentrations of GH in FM obese patients (all
data and subjects with normal or low IGF-1 SDS values), who
underwent the combined GHRH plus arginine test. Data are
expressed as mean± SD. Please note that GH levels were
significantly higher at T30, T45, T60, and T90 versus T0 (p < 0 01)
when considering all data and the two subgroups with normal or
low IGF-1 SDS values. ∗p < 0 05 versus the corresponding time
point of the group with normal IGF-1 SDS values.
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Figure 2: GH peaks obtained in each of the 16 FM obese patients
who underwent the GHRH plus arginine test together with the
corresponding time points (i.e., Tmax).
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In this context, it is noteworthy that the majority of GH-
deficient cases reported in the literature have often have a
BMI> 30 kg/m2 [3, 14]. Furthermore, in the present study,
the group with low IGF-1 SDS values had significantly higher
BMI values when compared to the group with normal IGF-1
levels. Therefore, it is difficult to refer the high prevalence of
impairment in GH-IGF-1 axis to FM itself or to obesity that
is often associated with this rheumatologic condition. In our
study, the correlations of GH peak with some parameters of
body composition, together with the lack of any correlations
between GH peak and clinical (tender point score) or
biochemical (ESR and CRP) indices of FM severity, seem to
suggest that the latter hypothesis (i.e., obesity causing the
most cases of GHD or impairment in GH-IGF-1 axis) is more
convincing than the former one (i.e., FM causing the most
cases of GHD or impairment in GH-IGF-1 axis). However,
the association of both low IGF-1 SDS values and absent/
low GH-stimulated response in the same individuals is
suggestive of a clear-cut, though functional, GH deficient
status. In this respect, it is noteworthy that low IGF-1 levels
and altered GH-stimulated secretion in obesity seem to
identify a subset of subjects with an increased cardiovascular
risk [6].
Yuen et al. [14] showed that majority of FM patients with
low IGF-1 have an exuberant GH response to the GHRH plus
arginine stimulation, implying a diagnosis of GH resistance.
In our study, among the group with low IGF-1 levels, only
one patient (PT#16) exhibited a GH peak GH> 10 ng/ml
(at T45). Therefore, using the GHRH plus arginine test
might have overestimated GH response in any patient,
given the potential hypothalamic effects of arginine on
the “dysregulated” GH/IGF-1 axis present in FM. Further
studies with the adoption of different GH provocative tests
are mandatory to solve this intriguing issue.
As far as our study is concerned, some limitations are to
be considered. Firstly, we have recruited a limited number of
patients; therefore, our results should be considered only
preliminary. Secondly, we have enrolled only female patients;
since GH secretion is differently regulated by sex steroid
hormones [15], the present study should be replicated in a
group of male subjects, though the low prevalence of FM in
men might hamper the selection of an adequate number of
male subjects with both severe obesity and FM [1]. The third
issue is that, in the present study, to assess the body compo-
sition, we used bioelectrical impedance analysis throughout
population-specific equations developed in our laboratory
[19]. This method usually presents some limitations in
morbidly obese patients, due to the relatively increased
amount of total body water and a relative increase in extracel-
lular water, which can result in an underestimation of the
percentage of body fat and an overestimation of fat-free mass
in these subjects. Last of all, data about hypothalamic-
pituitary morphology are lacking due to technical problems
related to the extremely high BMI values of the GHD
patients, thus hampering to define the aetiology of the
impaired GH secretion in a better way.
Differently from other clinical studies on this topic
recruiting patients taking antidepressants, antiepileptic
drugs, tramadol, estrogens, and other medications, which
could have introduced biases for the relevant effects of these
drugs on GH secretion [4], a positive aspect of the present
study is represented by the fact that our patients were taking
no medications known to affect the endocrine system,
including the somatotropic axis.
In conclusion, the present study shows that a not
negligible subpopulation (25%) of patients with both FM
and severe obesity has low IGF-1 SDS values, 12.5% failing
also to normally respond to the GHRH plus arginine test.
This seems to be a consequence of the obese rather than
fibromyalgic condition, a conclusion that should be cau-
tiously considered because of the small number of patients
recruited. Although the results of the present study are
preliminary, GH responsiveness of patients with both FM
and severe obesity should be carefully evaluated, since GH
replacement therapy might potentially improve the clini-
cal symptoms and the general well-being of those with
GHD [5, 20].
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